Analysts Expect iTeos Therapeutics, Inc. (NASDAQ:ITOS) Will Post Quarterly Sales of $329.75 Million

Wall Street analysts predict that iTeos Therapeutics, Inc. (NASDAQ:ITOS) will report $329.75 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for iTeos Therapeutics’ earnings, with estimates ranging from $19.50 million to $640.00 million. The company is expected to announce its next earnings report on Thursday, November 11th.

On average, analysts expect that iTeos Therapeutics will report full-year sales of $439.67 million for the current year, with estimates ranging from $39.00 million to $655.00 million. For the next financial year, analysts forecast that the company will post sales of $69.06 million, with estimates ranging from $60.00 million to $78.13 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for iTeos Therapeutics.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings data on Thursday, August 12th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.34).

A number of brokerages recently commented on ITOS. Zacks Investment Research upgraded shares of iTeos Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, August 30th. SVB Leerink dropped their price objective on shares of iTeos Therapeutics from $56.00 to $55.00 and set an “outperform” rating on the stock in a report on Friday, August 13th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, iTeos Therapeutics presently has a consensus rating of “Buy” and an average target price of $47.25.

In related news, CEO Michel Detheux sold 8,248 shares of iTeos Therapeutics stock in a transaction dated Friday, August 27th. The shares were sold at an average price of $28.17, for a total transaction of $232,346.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm sold 14,294 shares of the business’s stock in a transaction dated Wednesday, September 22nd. The shares were sold at an average price of $27.54, for a total transaction of $393,656.76. The disclosure for this sale can be found here. In the last three months, insiders sold 260,822 shares of company stock valued at $7,405,358. Insiders own 3.95% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace LLP acquired a new position in iTeos Therapeutics during the 2nd quarter worth approximately $3,666,000. Marshall Wace North America L.P. bought a new stake in iTeos Therapeutics during the 2nd quarter worth approximately $5,416,000. Morgan Stanley boosted its stake in shares of iTeos Therapeutics by 62,469.9% in the 2nd quarter. Morgan Stanley now owns 91,352 shares of the company’s stock valued at $2,344,000 after purchasing an additional 91,206 shares during the last quarter. Metropolitan Life Insurance Co NY boosted its stake in shares of iTeos Therapeutics by 110,800.0% in the 2nd quarter. Metropolitan Life Insurance Co NY now owns 6,654 shares of the company’s stock valued at $171,000 after purchasing an additional 6,648 shares during the last quarter. Finally, Boothbay Fund Management LLC bought a new stake in shares of iTeos Therapeutics in the 2nd quarter valued at $234,000. Institutional investors and hedge funds own 83.69% of the company’s stock.

ITOS traded down $0.21 during mid-day trading on Friday, hitting $27.25. The stock had a trading volume of 2,121 shares, compared to its average volume of 326,354. The stock’s fifty day simple moving average is $26.41 and its 200-day simple moving average is $26.12. The firm has a market capitalization of $959.47 million, a price-to-earnings ratio of -13.40 and a beta of 2.43. iTeos Therapeutics has a 1-year low of $17.43 and a 1-year high of $47.61.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

Featured Article: Call Option

Get a free copy of the Zacks research report on iTeos Therapeutics (ITOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for iTeos Therapeutics (NASDAQ:ITOS)

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.